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(1) Chronic hepatitis B virus (HBV) infections represent the major cause of HCC in China. (2) Tumor relapse and metastasis, two key features of HCC, are responsible for the poor prognosis. Elucidating the molecular mechanisms of HCC initiation and progression may lead to improved diagnostic and therapeutic strategies. Therefore, studies in this field aiming to identify reliable early diagnostic biomarkers and effective treatment options are urgently needed.
Alternative splicing generates different mature mRNAs from a single gene through selection of different exons to increase transcriptome and proteome diversity. (3) Aberrant alternative splicing events are commonly observed in cancer cells and contribute to tumor progression. (4) Cancer-specific mRNA transcripts, produced by interactions between cellular splicing factors and pre-mRNAs, may result in either activation of oncogenes or inactivation of tumor-suppressor genes, eventually leading to tumor invasion and metastasis. (5) p73 is alternatively spliced by amphiregulin into its oncogenic isoform, ΔEx2p73, during liver tumorigenesis. (6) Two Numb splice variants manifested opposite effects on HCC cell proliferation. (7) Alternative splicing of CD44, modulated by HNRNPLL, triggers an epithelial-mesenchymal transition (EMT) that promotes colorectal cancer metastasis. (8) A recent discovery demonstrated that the presence of a splice variant of the androgen receptor, AR-V7 (androgen receptor splice variant-7), in circulating tumor cells of patients with castration-resistant prostates, predicted a poor response to androgen-targeting drugs. (9) A splice variant that lacks exon 6 of coiled-coil domain containing 50 (CCDC50) was reported to inhibit the down-regulation of epidermal growth factor receptor (EGFR). (10) Our data of high-throughput RNA sequencing (RNASeq) revealed that CCDC50 pre-mRNA was aberrantly spliced in 50% of our HCC cases. However, the functional consequences and clinical significance of such an event are still undefined.
CCDC50 was first identified as a gene encoded from chromosome 3 open reading frame 6, mapping to chromosome 3q28, within the critical region of hereditary spastic paraplegia SPD14 locus. (11) CCDC50 has been characterized as a tyrosine-phosphorylated protein, and tyrosine phosphorylation of CCDC50 inhibits the nuclear factor kappa B (NF-κB)-mediated apoptotic pathway. (11) CCDC50 also plays a crucial role in the development and functional maturation of the inner ear and was responsible for DFNA44 hearing loss in a Spanish family. (12) In chronic lymphocytic leukemia and mantle cell lymphoma, CCDC50 is required for cell survival through the NF-κB and p53 signaling pathways. (13) However, little is known about the role of CCDC50 in solid cancers.
In this study, we demonstrated that up-regulation of CCDC50S, a truncated splice variant of CCDC50, is modulated by HBV-encoded X protein (HBx)-mediated cytosolic serine/arginine-rich splicing factor 3 (SRSF3) and functions as an oncogene in promoting tumor growth and metastasis in HCC through the Ras/forkhead box protein O4 (Foxo4) signaling pathway. High expression of CCDC50S is of promising diagnostic and prognostic implications for HCC. The HBx/SRSF3/CCDC50S/Foxo4 axis represents a potential therapeutic target for HCC intervention. 
Materials and Methods

tISSUe MICRoaRRay CoNStRUCtIoN aND IMMUNoHIStoCHeMIStRy eValUatIoN
Tissue microarrays (TMAs) were constructed in accord with a described protocol. (14) Specimens were selected and re-embedded into new paraffin blocks for TMA. TMA blocks were cut into 4-μm sections and underwent immunohistochemistry (IHC) staining. Protein expression levels of CCDC50 (1:3,000 dilution), SRSF3 (1:3,000 dilution), and Foxo4 (1:100 dilution) stained TMA slides were assessed by two independent pathologists. Median of the IHC score was chosen as the cut-off value for the high-and low-expression groups.
Cell lINeS aND Cell CUltURe
Eleven HCC cell lines (Bel-7402, Bel-7404, QGY-7701, QGY-7703, Huh7, MHCC-97H, MHCC-97L, HepG2, HepG2.2.15, HepG2-GFP, and HepG2-HBx-GFP) and two normal hepatic cell lines (L-02, QSG7701) were routinely cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, USA) and maintained at 37°C with 5% CO 2 , in accord with a described protocol. (15) plaSMID CoNStRUCtIoN aND tRaNSFeCtIoN CCDC50S and scrambled pENTER vector were purchased from Vigene Biosciences. CMVmyc SRSF3 and empty vector (CMVmyc pA) were obtained from Cochrane Lab (Toronto University, Toronto, Ontario, Canada). The recombinant plasmids pcDNA 3.1/hygro (+) empty vector, as well as pcDNA 3.1/hygro(+)-HA-HBx, were confirmed by sequencing. Plasmids were transfected into HCC cell lines using Lipofectamine 2000 (Invitrogen, NY, USA) reagent.
aNIMal MoDel
HCC models in nude mice were constructed as described. (15) Five-week-old male BALB/c nude mice were purchased from the Vital River Company (Beijing, China). For the subcutaneous injection model, 1 × 10 7 Bel-7404 or Bel-7402 cells were implanted subcutaneously. Tumor sizes were measured every 5 days. After 25 days, subcutaneous tumors were surgically excised and weighted. For the caudal vein injection model, 1 × 10 6 Bel-7404 or Bel-7402 cells in serum-free DMEM media were injected into the tail vein. After 35 days, lungs were resected and fixed for paraffin embedding in preparation for hematoxylin and eosin (H&E) staining. All animal studies were approved and performed by the animal institute of Sun Yat-sen University Cancer Center in accord with the protocols approved by the Medical Experimental Animal Care Commission of SYSUCC.
Real-tIMe ReVeRSetRaNSCRIptaSe pCR aND RNa StaBIlIty aSSay
Total RNA was extracted by TRIzol reagent (Invitrogen, NY, USA). Cytoplasmic and nuclear RNA were isolated and purified using the Cytoplasmic and Nuclear RNA Purification kit (Norgen, Thorold, ON, Canada), according to the manufacturer's instructions. Reverse-transcription and SYBR green-based real-time PCR were then carried out, in accord with a described protocol. (16) For CCDC50S mRNA stability analysis, a time-course analysis was performed using the transcription inhibitor, actinomycin D (30 μg/mL). Half-life of CCDC50S mRNA was calculated by densitometry analysis of the PCR product in an ethidium bromide-stained 1.5% agarose gel.
RNa IMMUNopReCIpItatIoN
RNA immunoprecipitation (RNA-IP) experiments were performed using a Millipore EZ-Magna radioimmunoprecipitation (RIP) RNA-Binding Protein Immunoprecipitation kit (Millipore 17-701), according to the manufacturer's instructions. The SRSF3 antibody (Abcam, ab198291) was used in RIP and mouse immunoglobulin G (IgG) was used as a negative control.
RNa IN SITU HyBRIDIZatIoN
RNA in situ hybridization (RISH) was performed using BaseScope technology (Advanced Cell Diagnostics, Hayward, CA), following the manufacturer's protocol and with minor modifications. HCC TMA sections were treated with hydrogen peroxide for 10 minutes at room temperature, followed by boiling in Target Retrieval for 15 minutes. Protease Plus was then added to samples for 15 minutes at room temperature. Sections were rinsed five times with distilled water, followed by hybridization with BaseScope probes, positive control, and negative control, for 2.5 hours at 40°C. Slices were then sequentially treated with AMP 0-6. Finally, Fast RED-A and Fast RED-B were mixed to mark the BaseScope probes. Sections were stained with 50% hematoxylin to highlight the nuclei. The probe for CCDC50S was designed to target the CCDC50S-specific junction of exon 5 and exon 7 (1ZZ probe targeting 1001-1050 of NM_174908.3), as illustrated in Fig. 1A . Staining intensity was jointly scored by two pathologists without knowledge of clinical information, on a scale of 0-4, with 0 = no staining, 1 ≤ 1 dot to every 10 cells, 2 > 1 dot to every 10 cells and <1 dot/cell, 3 = 1 dot/cell, 4 ≥ 2 dots/cell (Supporting Fig. S2 ). Scores 0-1 and scores 2-4 indicated negative and positive expressions of CCDC50S mRNA, respectively.
RNa-SeQ aND Data aNalySIS
Tumor and adjacent normal tissues of 8 HCC patients obtained from the SYSUCC were selected as a discovery cohort for RNA-Seq. Alternative splicing events were detected by the software MISO (mixture of isoforms). Differential splicing events were further identified according to Bayes factors calculated by MISO and filtering criteria, Psi values (Ψ), and confidence intervals, when comparing tumor and adjacent normal samples. Raw sequence data and processed data were submitted to the Gene Expression Omnibus (GEO) with an accession number of GSE104310. Total RNA isolated from Bel-7404 cells transfected with siCCDC50S and control small interfering RNA (siRNA) were subjected to paired-end RNA-Seq using the Illumina HiSeq 2000 system according to the manufacturer's instructions. The sequencing library was built and sequenced using the Illumina HiSeq 2000 by Guangzhou Gene Denovo Biological Technology Co., Ltd (Guangzhou, China). Raw sequence data and processed data were submitted to the GEO with an accession number of SRP120056. RNA-Seq data from the Cancer Genome Atlas (TCGA) was obtained from the TCGA Portal (https://tcga-data.nci.nih.gov).
StatIStICal aNalySIS
Statistical analyses were performed using SPSS (version 19.0) and GraphPad Prism (version 7.0). The Student t test, Pearson's χ 2 test, the KaplanMeier method, and a multivariate Cox proportional hazards regression model were used. Receiver operating characteristic (ROC) curve analysis was used to determine the cutpoint for marker positivity by the 0,1-criterion, and the sensitivity, specificity, and areas under the ROC curves (AUCs) were calculated. In all tests, results were considered statistically significant at P < 0.05 (two-tailed). 
Results
CCDC50S eXpReSSIoN IS INCReaSeD IN HCC aND CoRRelateD WItH pooR oUtCoMeS
Highly recurrent splicing alterations were first identified in eight HCC-adjacent normal pair-wise comparisons. CCDC50 is one of the most frequently differentially spliced genes (Supporting Table S1 ), generating two transcript variants dependent on the inclusion/exclusion of exon 6. CCDC50S (short isoform lacking alternative exon 6) represents the major form in HCC tissues, whereas CCDC50L (long isoform including alternative exon 6) shows relatively low expression (Fig. 1A) . In clinical samples, CCDC50S mRNA and protein levels were significantly upregulated in tumors compared to matched adjacent nontumor liver tissues (Fig. 1B,C) , whereas expression of CCDC50L remained unchanged (Supporting Fig.  S1A,B) . CCDC50S expression levels in most HCC cell lines were higher than those in immortalized hepatic cell lines (L-02 and QSG-7701; Supporting Fig. S1C) .
A BaseScope assay was performed with a custom-designed in situ hybridization probe named BA-Hs-CCDC50-tv1-E5E6 (Advanced Cell Diagnostics) to determine expression of CCDC50S in paraffin-embedded tissues. Scoring standards of BaseScope staining were based on the percentage of positive cancer cells compared with positive and negative control experiments used as a reference (Supporting Fig. S2A,B) . CCDC50S mRNA signal was recognized as relatively small dots located in the cytoplasm and exhibited significantly higher staining density in HCC tissues ( Fig. 1D and Supporting Fig. S2C ). Statistical analysis showed that high CCDC50S mRNA expression was associated with poor tumor cell differentiation, advanced tumor node metastasis (TNM) stage, and shorter overall survival ( Fig. 1E ; Supporting Table S2 ). Stratified survival analyses as well as uni-and multivariate analyses further confirmed the prognostic value of CCDC50S mRNA (Supporting Fig. S3 ; Supporting Table S3 ). Results of CCDC50S expression and clinical prognosis were also validated by TCGA data set (Supporting Fig. S4 ). CCDC50S mRNA, rather than CCDC50L mRNA, was significantly associated with overall survival (OS) in patients with HCC (Supporting Fig. S4) . Results of TMA-based IHC showed that CCDC50 protein expression level was gradually increased from nontumorous, HCC, and metastatic tissues (Supporting Fig. S5A,C) . High expression of CCDC50 was associated with OS, but not disease-free survival (DFS) of patients with HCC (Supporting Fig. S5B,D) .
Another 69 HCC cases with portal vein embolus were recruited to examine expression of CCDC50S in tumor metastatic tissues. Stronger staining of CCDC50S mRNA was visible in the HCC embolus compared to primary lesions (Fig. 1F) . Kaplan-Meier analysis revealed no significance of CCDC50S mRNA expression in predicting DFS in HCC (Supporting Fig. S1D ).
eXpReSSIoN oF CCDC50S MRNa IS oF poteNtIal DIagNoStIC SIgNIFICaNCe IN HCC
The finding that CCDC50S expression was reduced in esophageal, breast and colorectal cancer by qRT-PCR prompted us to examine the specificity of CCDC50S up-regulation in HCC (Supporting Fig. S6 ). We next validated the presence and quantitated the expression of CCDC50S in different tumors by BaseScope assay. Strikingly, in benign hepatic diseases and eight other types of solid tumors, the BaseScope signal of CCDC50S mRNA was relatively negative (Fig. 2A,B and Supporting Fig. S7A,B) . The positive ratio of CCDC50S in adjacent nontumorous liver tissues, DN, FNH, HCA, and PEComa was 3.98%, 0.00%, 0.00%, 0.00%, and 0.00%, respectively. In contrast, the relative ratio was elevated to approximately 46.48% in HCC. Weak CCDC50S mRNA was detected in intrahepatic CCA and colorectal cancer, but not in breast, esophageal, gastric, lung, kidney, and pancreatic cancers (Fig. 2B,C) . Sensitivity, specificity, and AUC for diagnosis of HCC versus other detected tumors using expression levels of CCDC50S mRNA were 71.1%, 79.3%, and 0.783, respectively (Fig.  2D) . Sensitivity, specificity, and AUC values for HCC diagnosis were 50.0%, 73.6%, and 0.615 when alpha-fetoprotein (AFP) was detected by IHC. A comparison for ROC curves showed that the AUC for CCDC50S mRNA was significantly larger than that for AFP (P < 0.0001), whereas there were no significant differences of AUC between the combination and CCDC50S mRNA alone (P = 0.095). These values indicate that CCDC50S mRNA is a potential diagnostic marker for HCC, and, compared to AFP, CCDC50S mRNA could greatly improve the diagnostic accuracy of HCC.
CCDC50S eXeRtS oNCogeNIC aCtIVItIeS IN VIVO aND IN VITRO
To explore the biological role of CCDC50S in HCC, CCDC50S was either silenced or overexpressed in Bel-7404 and Bel-7402 cells (Supporting S8 ). Colony formation assays showed that cell proliferation was decreased in siCCDC50S-transfected cells, but increased in CCDC50S-overexpressing cells, compared to corresponding control groups (Fig. 3A) . This was confirmed by (5-ethynyl-2'-deoxyuridine) and 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide assays ( Fig. 3B and Supporting Fig. S9A ). Furthermore, HCC cells transfected with siCCDC50S exhibited a relatively higher rate of cell apoptosis than that of cells transfected with the scrambled controls (Supporting Fig. S9B) . Results of functional experiments indicated that no significant effects were observed with regard to HCC cells of CCDC50L knockdown (Supporting Fig. S10A,B) . To examine the effect of CCDC50S in vivo, we used a BALB/C nude mouse model with xenografts formed by either CCDC50S knockdown or overexpression cells. The CCDC50S-silenced group induced remarkably smaller tumors than the CCDC50S scrambled group. Tumors from mice injected with CCDC50S-overexpressing cells were larger than those in the empty vector group (Fig. 3C ). There was a marked difference in final mean tumor volume and mass (Supporting Fig. S9C,D) .
Because the clinical data implied that CCDC50S might participate in HCC metastasis, the impact of CCDC50S in cell motility was examined. Transwell assays showed that knockdown of CCDC50S, but not CCDC50L, reduced, whereas exogenous expression of CCDC50S enhanced the ability of cell migration in HCC cells (Fig. 3D and Supporting Fig. S10C) . Wound healing assays further demonstrated that CCDC50S-overexpressing cells enhanced migration of cells toward the artificially created wound than in the control group (Supporting Fig. S11A ). Cell pseudopodia was increased in CCDC50S-overexpressing cells, but retracted in siCCDC50S transfected cells (Supporting Fig. S11B ). Caudal vein injection models were established to examine the effect of CCDC50S on tumor metastasis in vivo. Metastatic foci in lung sections were confirmed by H&E staining, and depicted in Fig. 3E . Statistical analysis indicated that the number of metastatic nodules in the lung in CCDC50S-depleted groups was less frequently observed than those in control groups (Fig. 3E) . Collectively, these results suggest that CCDC50S was capable of promoting HCC progression in vitro and in vivo.
CCDC50S SUppReSSeS FoXo4 eXpReSSIoN tHRoUgH tHe RaS SIgNalINg patHWay
To further uncover the molecular mechanism of CCDC50S-promoted cell growth, transcriptome profiling by RNA-Seq was conducted. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis showed that the Ras signaling pathway was significantly altered by knockdown of CCDC50S (Fig. 4A) . Co-immunoprecipitation (Co-IP) data showed that CCDC50S directly bound to EGFR (a well-known upstream regulator of Ras signaling) and enhanced its protein stability (Supporting Fig. S12A,B) . Knockdown of EGFR significantly attenuated CCDC50S-induced cell proliferation and migration (Supporting Fig. S12C,D) . Furthermore, phosphorylation of protein kinase B (AKT) and proteins involved in EGRF/Ras signaling, such as extracellular signal-regulated kinase (ERK), mitogen-activated protein kinase kinase (MEK), and c-raf, was decreased in cells transfected with siC-CDC50S, but increased in CCDC50S-overexpressing cells (Fig. 4B ). Both treatments of PD98059 (MEK inhibitor) and PD0325901 (ERK inhibitor), but not AKT inhibitor-IV (Supporting Fig. S13 ), attenuated cell proliferation or migration induced by CCDC50S overexpression, as shown in colony formation and transwell assays (Fig. 4C,D) .
We next intended to identify the downstream effector of CCDC50S in HCC. Among the Rasrelated genes with significant altered expression by CCDC50S knockdown, Foxo4 was of the most up-regulation. As a result, Foxo4 was chosen for further investigations. Overexpression of CCDC50S markedly suppressed, whereas silence of CCDC50S induced, mRNA and protein expression of Foxo4, which was down-regulated in HCC (Fig. 4E,F) . However, phosphorylation of Foxo4 was not affected in cells with either CCDC50S overexpression or depletion (Supporting Fig. S14) . A reverse correlation was found between expression of CCDC50 and Foxo4 (Fig. 4F) . Downregulation of Foxo4 by CCDC50S was abolished by treatment of PD0325901 (ERK inhibitor), but not of AKT inhibitor-IV (Supporting Fig. S15A ), suggesting an essential role of ERK in CCDC50S-mediated regulation of Foxo4. A Luciferase reporter assay demonstrated that EKR inhibition enhanced promoter activity of Foxo4 (Supporting Fig. S15B ). In addition, Foxo4 depletion significantly attenuated CCDC50S siRNA-mediated suppression of cell growth and migration, whereas Foxo4 overexpression partially reversed CCDC50S-mediated phenotypes (Supporting Fig. S16 ). These results indicated that CCDC50S exerted oncogenic functions in HCC through the Ras/Foxo4 pathway.
CCDC50S MRNa IS RegUlateD By SRSF3
A catalogue of annotated splicing factor genes, based on Gene Ontology accessions, (3) TCGA data sets, and our RNA-Seq data (GSE104310), was analyzed to identify the upstream regulator of CCDC50S. The heatmap summarized the correlation results between splicing associated genes and CCDC50S mRNA (Supporting Fig. S17A ). Six genes, including SRSF3, were found by coexpression analysis (Supporting Fig. S17B ). SRSF3 mRNA and protein levels were significantly increased in HCC compared to matched adjacent nontumor live tissues (Supporting Fig. S18A,B) . A positive association was depicted between the SRSF3 mRNA and CCDC50S mRNA determined by qRT-PCR (Supporting Fig. S18C ). Interestingly, SRSF3 was observed predominantly in the cytoplasm of HCC tissues, whereas it was mainly expressed in the nucleus of adjacent liver tissues (Supporting Fig.  S18D ). In contrast with nuclear SRSF3, expression of cytosolic SRSF3 was up-regulated in HCC and correlated with poor OS (Supporting Fig. S18E ). Specifically, cytoplasmic SRSF3 expression was significantly associated with the CCDC50S mRNA determined by BaseScope or the CCDC50 protein determined by IHC in HCC samples ( Fig. 5A and Supporting Fig. S18F) . In vitro data demonstrated that SRSF3 manifested protumor activities that promoted cell proliferation and migration in HCC cells (Supporting Fig. S19 ).
We next investigated the molecular mechanism of SRSF3 regulation on CCDC50S in HCC. Depletion of SRSF3 by siRNA reduced, whereas overexpression of SRSF3 induced CCDC50S mRNA and protein expression (Fig. 5B,C) . Upon the silence of SRSF3, CCDC50S mRNA was increased in nucleus, but decreased in cytoplasm, in both Bel-7404 and Bel-7402 cells (Fig. 5D) . Furthermore, CCDC50S knockdown partially rescued the cell proliferation and migration induced by ectopic expression of SRSF3, and CCDC50S overexpression abolished the suppression of cell growth mediated by SRSF3 siRNA (Supporting Fig. S20 ).
Whether SRSF3 modulated CCDC50S mRNA at a posttranscriptional level was next determined, using RNA-IP assays. Results showed that SRSF3 directly bound to CCDC50S mRNA (Fig. 5E ). qRT-PCR data revealed a 9.5-fold enrichment for interaction of SRSF3 and CCDC50S (Fig. 5E ). In cells with SRSF3 depletion, degradation of cytosolic CCDC50S mRNA was significantly accelerated (Fig. 5F ). Halflife of CCDC50S mRNA was remarkably shortened by SRSF3 siRNA (Fig. 5F ). In contrast, stability of CCDC50S mRNA was enhanced by SRSF3 overexpression (Supporting Fig. S21 ). These data suggest cytosolic SRSF3 directly binds to CCDC50S mRNA to maintain its stability in HCC cells.
HBx MeDIateS tHe SUBCellUlaR loCalIZatIoN oF SRSF3
Expression of CCDC50S mRNA and protein was increased in HepG2.2.15 cells (HBV positive) compared to HepG2 cells (HBV negative; Fig. 6A ). IHC data demonstrated that among common solid tumors, cytoplasmic SRSF3 was only depicted in HCC with HBV infection (Fig. 6B and Supporting  Fig. S22) . A positive correlation was found between expression of HBx and cytoplasmic SRSF3 (Fig. 6B) . We next examined whether HBx was involved in the regulation of SRSF3 subcellular localization. HBx expression was found in MHCC97H, MHCC97L, HepG2.2.15, and HepG2-HBx-GFP cells (Supporting Fig. S23A ). In HBx-expressing cells, SRSF3 was predominantly localized to the cytoplasm. SRSF3 could be also detected in the nucleus in cells without HBx expression (Supporting Fig. S23B ). In HBx-expressing HepG2.2.15 and HepG2-HBx-GFP cells, SRSF3 protein level was up-regulated in cytoplasm, but down-regulated in nuclear, compared to that in HBx-negative HepG2 and HepG2-GFP cells (Fig. 6C) . Treatment of HBx siRNA in HepG2.2.15 and HepG2-HBx-GFP cells resulted in nuclear translocation of SRSF3 (Fig. 6D) . This was consistent with results from western blotting analysis (Fig.  6D) . Deletion mutants of HBx were constructed to examine the effect of N-and C-terminal HBx on the distribution of SRSF3 (Supporting Fig. S23C ). Overexpression of an HBx N-terminal mutant, but not C-terminal mutant, was capable of nucleocytoplasmic redistribution of SRSF3 (Supporting Fig. S23D ). Fulllength and N-terminal HBx directly bound to SRSF3, as shown by a Co-IP assay using HepG2-HBx-GFP and Bel-7402 cells with HBx overexpression (Fig.  6E2) . Colocalization of HBx and SRSF3 in the cytoplasm was observed by an immunofluorescence staining (Fig. 6E1) . Through bioinformatics analysis, a set of proteins interacting with both SRSF3 and HBx was visualized by Cytoscape software (version 3.6.1), and 14-3-3β was found as one of the junction points in the protein-protein network (Supporting Fig. S23E ). We performed Co-IP assays to verify the interactions of 14-3-3β, HBx, and SRSF3 in both HBx-negative and -positive cells. Results demonstrated that interaction of SRSF3 and 14-3-3β was enhanced by HBx (Fig. 6E2) . Knockdown of 14-3-3β could remarkably suppress cytoplasmic retention of SRSF3 (Fig. 6F) .
Taken together, these results indicated that HBx contributed to 14-3-3β-mediated cytoplasmic retention of SRSF3 through protein interactions.
Discussion
Liver cancer is the second-leading cause of cancer-related death in men worldwide.
(1) Chronic infection with HBV is a major risk factor for HCC. (2) Extensive research has been conducted to elucidate the molecular events underlying HCC development and invasion. However, the carcinogenic mechanisms involved in this process are far from clear. Alternative splicing has critical roles in promoting cancer growth and survival. Splicing factor genes are significantly differentially expressed between cancer and corresponding normal samples. (3) To better understand HCC biology and explore potential biomarkers and therapeutic targets, we analyzed transcriptome sequencing and identified CCDC50, a unique signature of alternative splicing genes which is dysregulated in HCC.
CCDC50 is a multifunctional regulator of inflammation, cell death, and proliferation. CCDC50 is therefore presumed to be closely related to growth factor signaling or carcinogenesis. (17) In researching the biological consequences of elevated CCDC50S expression in HCC, we provided multiple lines of evidence to demonstrate that CCDC50S accelerates proliferation and promotes migration of HCC cells in vitro and in vivo. These functional characteristics of CCDC50S are consistent with our analysis of clinical data, indicating that HCC patients whose tumors are characterized by high CCDC50S expression fared poorly with respect to OS rates.
We developed a RISH detection method targeting a single-splice junction, using probes straddling the Relative subcellular expression levels of SRSF3 (red) were determined using confocal microscopy. (E) E1. Co-Immunoprecipitation assays were performed to determine the interaction between HBx and SRSF3 in HepG2-HBx cells, and interaction between HBx, 14-3-3-β and SRSF3 HepG2-HBx-GFP cells. E2. Confocal immunofluorescence analysis of the subcellular distribution of SRSF3 and HBx protein in HepG2-GFP-HBx. Immunofluorescence staining indicating GFP-HBx (green) and SRSF3 (red) together with DAPI (blue) showed the co-localization of HBx and SRSF3 in HepG2-GFP-HBx. F. HepG2.2.15 and HepG2-HBx-GFP cells were transfected with si14-3-3-β for 48h, and then cytoplasmic and nuclear extracts from an equal number of cells were subjected to western blotting analysis. β-tubulin and LaminB were respectively used as loading controls for cytoplasmic and nuclear fractions. Quantitative data are presented as mean ± SEM. Abbreviations: GFP, green fluorescent protein; IB, immunoblotting; IP, immunoprecipitation; NC, normal control. targeted junction. We applied this method to detect and quantify CCDC50S by targeting the exon 5/exon 7 junction. The BaseScope technique has already been used to detect AR-V7 levels in prostate cancer. (18) In the present study, strong staining of CCDC50S mRNA using BaseScope assays was positively detected in HCC samples compared with other common human malignancies and tissues of benign hepatic diseases. Moreover, CCDC50S mRNA showed a higher sensitivity, specificity, and AUC than AFP for HCC detection. Therefore, expression of CCDC50S may serve as not only a useful diagnostic and prognostic biomarker, but also as a potential therapeutic intervention for HCC. Detailed research and further validation are required to evaluate the clinical role of CCDC50S.
Alternative splicing is regulated by interactions between cellular splicing factors and RNA sequences in pre-mRNA. (19) Alteration of splicing factor levels and activities is a main cause of splicing dysregulation in retinopathies, motor neuron disease, and especially in cancer. (3, 20) As one of the splicing factors, Ser/ Arg-rich (SR) proteins are composed of a C-terminal domain enriched with SR repeats for spliceosome recruitment, preceded by at least one N-terminal RNA-binding domain of the RNA recognition motif type. (21) SRSF3 is the smallest member of the highly conserved SR-rich splicing factor family. (22) Besides its regulation of RNA splicing, SRSF3 is also involved in other important cellular functions, such as cell-cycle control and embryogenesis. (23) SRSF3 regulates glucose and lipid metabolism in the liver, as well as hepatocyte maturation and differentiation. (24) SRSF3 is also a proto-oncogene whose expression is up-regulated in various human tumors, such as ovarian cancer and colon cancer. (22) Down-regulation of SRSF3 induces p53b expression, an abnormal alternatively spliced transcript of p53 that leads to cellular senescence. (25) As a crucial regulator in hepatocytes, SRSF3 can lead to steatosis, fibrosis, mitogenesis, EMT, and eventually to HCC. (23) We noticed that increased CCDC50S mRNA levels have a significantly positive correlation with elevated cytoplasmic expression of SRSF3 in 417 clinical HCC samples. Intriguingly, IHC results showed that SRSF3 staining was cytoplasmic in HCC samples, whereas staining was nuclear in adjacent liver tissues. A previous study revealed that several SR proteins, such as SRSF1 and SRSF3, shuttle between the nucleus and cytoplasm at a highly dynamic rate. (21) In the nucleus, SRSF3 has essential roles in pre-mRNA splicing, which are primarily associated with cell proliferation and cell cycle. (26) Direct effects of SRSF1 on cytoplasmic mRNA metabolism are diverse and include regulation of mRNA stability and translation. (27) Our data suggest that reduced SRSF3 expression in the nucleus resulted in promoting the skipping of CCDC50 exon 6. Increased cytoplasmic SRSR3 expression led to maintaining the stability of CCDC50S mRNA. In the current study, misdistribution of SRSF3 in HCC cells favored CCDC50S expression. These results underscore the importance of SRSF3 in CCDC50S regulation and further emphasize the importance of splicing control in HCC. The mechanistic link between splicing factors and CCDC50S splicing is still a subject of ongoing investigation.
HBx, a key oncogenic protein encoded by the HBV X gene, plays an essential role in HBV-induced HCC. (28) HBx modulates a series of cytoplasmic signaling pathways, closely correlated to tumor growth and metastasis, through protein-protein interactions. (29) Human papillomaviruses (HPVs) are another group of tumor-related, DNA viruses similar to HBV. HPV16 oncoproteins and Ser/Arg-rich splicing factors (SRSFs) are mutually regulated and jointly maintain cervical tumor progression. (27) However, few studies have clarified the associations between HBx and splicing factors. During coxsackievirus B3, human rhinovirus 16, or human rhinovirus 16 infection, SRSF3 relocalizes from the nucleus to the cytoplasm. (30) Some virus proteins, like those of Epstein Barr virus and HPV, can exploit SRSF3 to facilitate their mRNA's nuclear export, cytoplasmic accumulation, and translation by different mechanisms. (31) Accumulated evidence has shown that HBx acts as a multifunctional oncoprotein in the development of HCC, and that it is mostly localized to the cytoplasm, and the nucleus to a lesser extent. (32) It has been suggested that HBx exerts its carcinogenic effects by inducing genetic alterations in tumor-suppressor genes and oncogenes and activating a variety of cellular signaling pathways related to cell cycle, proliferation, and apoptosis. (28) On the other hand, HBx exhibited functions through alteration of cellular localization of proteins involved in cell growth. For example, HBx bound to murine double minute 2 (MDM2) and promoted its translocation into the nucleus, resulting in enhanced transcriptional activity of MDM2. (33) Our data demonstrated that HBx enhanced 14-3-3β-mediated cytoplasmic retaining of SRSF3.
In conclusion, our data suggest the possibility that CCDC50S mRNA may represent a diagnostic biomarker for HCC. Because CCDC50S mRNA also predicts a poor prognosis, evaluation of CCDC50S mRNA as a treatment strategy for HCC patients warrants further clinical investigation. Our findings also provided evidence that HBx causes dysregulation of SRSF3 and affects splicing variant CCDC50S to contribute to growth and metastasis of HCC through the Ras/Foxo4 signaling pathway (Fig. 7) .
FIg. 7.
Schematic regulatory network of the HBx-mediated SRSF3-regulated splicing variant CCDC50S that promotes tumor growth and metastasis in HCC.Schematic regulatory network of the HBx-mediated SRSF3-regulated splicing variant CCDC50S that promotes tumor growth and metastasis in HCC. Abbreviation: p-, phosphorylated.
